Your search found 2 Results
Towards the creation of strategic partnerships: improving access to drugs for HIV / AIDS. Report of a consultative meeting, 30 June - 2 July 1997, Salle C, WHO, Geneva.
Geneva, Switzerland, UNAIDS, 1998. 20 p. (UNAIDS Best Practice Collection. Key Material; UNAIDS/98.40)From January 1996, the UNAIDS Secretariat has been in consultation with key players in the pharmaceutical industry, NGOs, people living with HIV, UN, major bilateral donors, country representatives and National AIDS Programme Managers on issues relating to access to drugs for HIV/AIDS. This meeting, held on 30 June to 2 July 1997, was the climax of this consultative process. The meeting brought together people living with HIV/AIDS, NGO representatives, National AIDS Programme Managers and UN representatives. With a modified version of the Search Conference approach, the following questions were raised: What are the current and future issues on access to drugs for HIV/AIDS at country and global levels? What partnerships should be created at country level to address these issues? What should be the content of these partnerships at country level? What should the UN do at global and country level to support these partnerships? To foster regional exchange of experience as well as enhance regional specificity, participants were assigned groups on a regional basis. (excerpt)
Lancet. 2005 Mar 26; 365:1198-1200.In the early 1990s, a subset of the health sector— patented drugs—burst quite unexpectedly into the international trade debate. The ongoing trade negotiations of the Uruguay Round were in disarray, and support from sectors that relied on the protection of intellectual property rights became essential to move them forward. Indeed, the Uruguay Round Agreement was signed in 1994 only because it included a then much praised Trade-Related Intellectual Property Rights (TRIPs) agreement. Between 1994 and the 2001 Doha Ministerial of the World Trade Organization (WTO), the spread of AIDS reached pandemic proportions. Research had yielded a cocktail therapeutic of drugs, but in 2001 a typical treatment cost US$12 000 a year per person—a sum far out of reach for most people with AIDS in developing countries. This imbalance fuelled a debate about access to essential medicines so acrimonious that it came close to derailing the Doha Ministerial. A solution was reached only 2 years later, and only 2 weeks before the 2003 Cancún WTO Ministerial. (excerpt)